Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for bioAffinity Technologies's EV-to-OCF or its related term are showing as below:
BIAF'
s EV-to-OCF Range Over the Past 10 Years
Min: -13.09 Med: -1.18 Max: 1.74
Current: -0.19
During the past 6 years, the highest EV-to-OCF of bioAffinity Technologies was 1.74. The lowest was -13.09. And the median was -1.18.
BIAF's EV-to-OCF is ranked better than 55.87% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 6.35
vs BIAF: -0.19
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
bioAffinity Technologies's PE Ratio (TTM) for today is calculated as:
bioAffinity Technologies's share price for today is $0.49.
bioAffinity Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.887.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
bioAffinity Technologies EV-to-OCF Related Terms
bioAffinity Technologies EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, bioAffinity Technologies's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioAffinity Technologies EV-to-OCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, bioAffinity Technologies's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where bioAffinity Technologies's EV-to-OCF falls into.
bioAffinity Technologies's current Enterprise Value is $2.08 Mil.
bioAffinity Technologies's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioAffinity Technologies (BIAF) has a EV-to-OCF of -0.19 as of Aug. 10, 2026. According to the industry distribution chart, bioAffinity Technologies ranks #94 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 44.1%.
Is bioAffinity Technologies' EV-to-OCF too high?
bioAffinity Technologies' current EV-to-OCF is -0.19. Based on the distribution chart, bioAffinity Technologies ranks #94 out of 213 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, bioAffinity Technologies has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioAffinity Technologies' EV-to-OCF compare to FUNI and ISPC?
According to the Medical Diagnostics & Research industry distribution chart, bioAffinity Technologies ranks #94 out of 213 companies for EV-to-OCF. This puts bioAffinity Technologies in the upper half of its industry. The industry median EV-to-OCF is 6.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Diagnostics & Research company?
The median EV-to-OCF among Medical Diagnostics & Research companies is 6.35, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median EV-to-OCF is 6.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioAffinity Technologies's current EV-to-OCF is -0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioAffinity Technologies stock overvalued right now?
Based on GuruFocus' analysis, bioAffinity Technologies (BIAF) is currently considered Possible Value Trap. The stock's GF Value™ is $5.71, compared to a current price of $0.49 — trading 91.4% below its estimated fair value. The current EV-to-OCF is -0.19. bioAffinity Technologies' overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For bioAffinity Technologies (BIAF), the current EV-to-OCF is -0.19 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioAffinity Technologies (BIAF) Overvalued in 2026?
Based on GuruFocus' analysis, bioAffinity Technologies stock appears to be undervalued.
The current stock price of $0.49 is trading 91.4% below its estimated GF Value™ of $5.71.
GuruFocus considers bioAffinity Technologies to be Possible Value Trap.
Key valuation signals for BIAF:
EV-to-OCF: -0.19
GF Value™: $5.71 vs. price of $0.49 (91.4% below fair value)
No single metric tells the full story. See the BIAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
44GF Score
Get the complete analysis for BIAF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BIAF has been successfully added to your 
